Biora Therapeutics granted extension by Nasdaq to meet market value and bid price requirements.

From GlobeNewswire: 2024-08-28 08:00:00

Biora Therapeutics, Inc. (Nasdaq: BIOR) has been granted an extension by Nasdaq to regain compliance with listing requirements. The company must meet a $50 million market value and $1 bid price by November 7, 2024, to remain on The Nasdaq Global Market. Biora Therapeutics is known for its NaviCap™ platform for colon-targeted IBD treatment and BioJet™ platform for oral delivery of large molecules. The company anticipates achieving milestones with their innovative therapeutics platforms. For more information, visit bioratherapeutics.com or follow the company on LinkedIn.



Read more at GlobeNewswire: Biora Therapeutics Announces Positive Nasdaq Listing